Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Genentech, Inc.
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Official title: A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
195
Start Date
2020-03-09
Completion Date
2026-06-15
Last Updated
2026-02-24
Healthy Volunteers
No
Conditions
Interventions
XmAb24306
Participants will receive intravenous (IV) XmAb24306.
Atezolizumab
Participants will receive IV XmAb24306 followed by IV atezolizumab
XmAb24306
Participants will receive IV XmAb24306 followed by IV atezolizumab.
Locations (25)
Honor Health Research Institute
Scottsdale, Arizona, United States
Stanford Health Centre - Palo Alto
Palo Alto, California, United States
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Yale University
New Haven, Connecticut, United States
City of Hope Comprehensive Cancer Center
Ann Arbor, Michigan, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Parkville Cancer Clinical Trial Unit (PCCTU)
Melbourne, Victoria, Australia
GasthuisZusters Antwerpen
Wilrijk, Antwerp, Belgium
Hospital de Clinicas de Porto Alegre HCPA PPDS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, Brazil
Princess Margaret Hospital
Toronto, Ontario, Canada
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, North Holland, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System - PPDS
Seoul, South Korea
Asan Medical Center - PPDS
Seoul, South Korea
Samsung Medical Center - PPDS
Seoul, South Korea
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Clinica Universidad de Navarra-Madrid
Madrid, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain